603676.SHG Tibet Weixinkang Medicine Co Ltd
- Market cap
- CNY 3.66B
- P/E
- 19.1x
- P/B
- 2.30x
- ROE
- 15.0%
- Dividend yield
- 4.47%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603676.SHG undervalued?
Graham number603676.SHG trades 39.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tibet Weixinkang Medicine Co Ltd fundamental analysis
No fundamental analysis for Tibet Weixinkang Medicine Co Ltd yet.
Tibet Weixinkang Medicine Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium aspartate, carbohydrate and electrolyte, pentoxifylline, piracetam, and dopamin…
Full company profileTibet Weixinkang Medicine Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tibet Weixinkang Medicine Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 426M | 420M | 746M | 741M | 716M | 1.03B | 1.40B | 1.32B | 1.30B | 1.14B | 1.09B |
| Gross Profit | 265M | 242M | 341M | 347M | 331M | 531M | 726M | 671M | 696M | 698M | 637M |
| Operating Income | 113M | 88.7M | 76.6M | 55.2M | 59.3M | 102M | 163M | 175M | 281M | 259M | 265M |
| EBITDA | 146M | 137M | 101M | 92.8M | 102M | 146M | 219M | 259M | 323M | 335M | 276M |
| Net Income | 115M | 102M | 73.4M | 55.7M | 58.4M | 95.9M | 177M | 214M | 246M | 233M | 235M |
| EPS | 0.32 | 0.26 | 0.17 | 0.13 | 0.14 | 0.23 | 0.41 | 0.50 | 0.57 | 0.54 | 0.54 |
| Balance Sheet | |||||||||||
| Total Assets | 552M | 1.02B | 1.23B | 1.30B | 1.36B | 1.50B | 1.66B | 1.78B | 1.85B | 1.87B | 1.96B |
| Total Liabilities | 92.9M | 159M | 337M | 375M | 377M | 428M | 444M | 437M | 468M | 390M | 382M |
| Shareholders' Equity | 459M | 858M | 898M | 930M | 983M | 1.07B | 1.22B | 1.34B | 1.39B | 1.48B | 1.57B |
| Cash & Short-term Investments | 89.3M | 75.4M | 154M | 530M | 576M | 712M | 806M | 895M | 1.02B | 212M | 92.4M |
| Total Debt | - | - | 26.6M | - | 6.35M | 4.81M | 5.79M | 3.82M | 5.27M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 104M | 63.3M | 83.2M | 106M | 134M | 171M | 246M | 257M | 373M | 186M | - |
| Capital Expenditure | 26.4M | 77.8M | 94.5M | 43.7M | 54.3M | 55.6M | 77.7M | 70.8M | 58.2M | 83.9M | 71.0M |
| Free Cash Flow | 77.4M | -14.5M | -11.3M | 62.7M | 79.3M | 115M | 168M | 170M | 315M | 102M | 126M |
| Ratios | |||||||||||
| ROE | 25.0% | 11.8% | 8.2% | 6.0% | 5.9% | 9.0% | 14.5% | 16.0% | 17.8% | 15.8% | 15.0% |
| ROA | 20.8% | 10.0% | 5.9% | 4.3% | 4.3% | 6.4% | 10.6% | 12.0% | 13.3% | 12.5% | 12.0% |
| Net Profit Margin | 27.0% | 24.2% | 9.8% | 7.5% | 8.2% | 9.3% | 12.7% | 16.2% | 18.9% | 20.5% | 21.6% |
| Debt to Equity | - | - | 0.03x | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tibet Weixinkang Medicine Co Ltd dividends
- Dividend yield
- 4.47%
- Forward dividend
- 0.33 CNY
- Payout ratio
- 70.2%
- Ex-dividend date
- Jun 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 163M | 0.38 | 70.2% |
| 2024 | CNY 178M | 0.41 | 72.2% |
| 2023 | CNY 97.8M | 0.23 | 45.7% |
| 2022 | CNY 69.6M | 0.16 | 39.3% |
| 2021 | CNY 40.2M | 0.10 | 41.9% |
| 2020 | CNY 19.0M | 0.05 | 32.6% |
| 2019 | CNY 23.3M | 0.05 | 41.8% |
| 2018 | CNY 34.4M | 0.08 | 46.8% |
| 2017 | CNY 3.45M | 0.01 | 3.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Tibet Weixinkang Medicine Co Ltd
- Insiders 78.05%
- Institutions 0.50%
- Public & others 21.46%
- Shares outstanding 435M
- Free float 92.6M
Tibet Weixinkang Medicine Co Ltd company profile
- Company name
- Tibet Weixinkang Medicine Co Ltd
- Ticker
- 603676.SHG
- ISIN
- CNE100002QQ3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 763
- Fiscal year end
- December
- Address
- Building 4, Lhasa, China, 850000
- Phone
- 86 10 5087 0199
- Website
- wxkpharma.com
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium aspartate, carbohydrate and electrolyte, pentoxifylline, piracetam, and dopamine hydrochloride injections; and acetylcysteine solution for inhalation. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2002 and is based in Lhasa, China.
Tibet Weixinkang Medicine Co Ltd management
7- Mr. Feng LiuVice Chairman & Deputy GM · born 1973
- Ms. Yanxia ZhengFinancial Director · born 1979
- Mr. Shigong ChenDeputy GM & Director · born 1973
- Mr. Haibo YuBoard Secretary · born 1979
- Mr. Xiaobing ZhouDeputy General Manager · born 1976
- Mr. Weiqiang LiuDeputy General Manager · born 1979
- Liqun YaoAccounting Supervisor